Inari Medical (NARI)
(Delayed Data from NSDQ)
$37.11 USD
-0.86 (-2.26%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $37.15 +0.04 (0.11%) 7:56 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Inari Medical, Inc. (NARI) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$73.70 | $100.00 | $47.00 | 94.31% |
Price Target
Based on short-term price targets offered by 10 analysts, the average price target for Inari Medical, Inc. comes to $73.70. The forecasts range from a low of $47.00 to a high of $100.00. The average price target represents an increase of 94.31% from the last closing price of $37.93.
Analyst Price Targets (10)
Broker Rating
Inari Medical, Inc. currently has an average brokerage recommendation (ABR) of 1.56 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.56 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, six are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 66.67% and 11.11% of all recommendations. A month ago, Strong Buy made up 66.67%, while Buy represented 11.11%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 6 | 7 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 2 | 2 | 2 | 2 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.56 | 1.56 | 1.56 | 1.56 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/12/2024 | Canaccord Genuity | William J Plovanic | Strong Buy | Strong Buy |
3/22/2024 | Truist Securities | Richard Newitter | Hold | Hold |
2/29/2024 | Needham & Company | Michael Matson | Moderate Buy | Moderate Buy |
2/29/2024 | Piper Sandler | Adam C Maeder | Strong Buy | Hold |
1/7/2024 | BTIG | Marie Thibault | Strong Buy | Strong Buy |
7/19/2023 | Robert W. Baird & Co. | David Rescott | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.56 |
ABR (Last week) | 1.56 |
# of Recs in ABR | 9 |
Average Target Price | $73.70 |
LT Growth Rate | NA |
Industry | Medical - Instruments |
Industry Rank by ABR | 89 of 252 |
Current Quarter EPS Est: | -0.16 |